An international team, led by scientists from the University of Cambridge, has conducted a groundbreaking early-stage clinical trial injecting neural stem cells into the brains of 15 patients with secondary progressive multiple sclerosis (MS). Derived from a single donor, these stem cells demonstrated safety, tolerability, and potential long-lasting effects, suggesting a protective impact on the brain. The study addresses the urgent need for treatments targeting progressive MS, a phase where disability worsens steadily despite available therapies. The researchers observed no treatment-related deaths or serious adverse events during the 12-month follow-up, with indications of stabilized disability levels and neuroprotective effects. While acknowledging study limitations, the team sees these results as a promising step towards developing cell therapy for treating MS.